Tue, Mar 19, 2024
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Private Equity Strategies

VC Spotlight: Fidelity Biosciences Merges with Devonshire Investors’ to form F-Prime Capital

Friday, October 09, 2015

Fidelity Biosciences, the bioscience investing arm of Fidelity Investments has merged with technology venture capital fund Devonshire Investors’ to become F-Prime Capital. F-Prime Capital will serve as a unified venture investing unit for FMR, the parent company of Fidelity Investments and will focus on backing life sciences, healthcare and technology companies.

“The two entities were already working together pretty extensively, so we thought it made since to join them,” says Michael Aalto, a spokesman for F-Prime Capital in an interview. “Fidelity has a long history in venture and this will allow us to present a clearer market presence.”

The name F-Prime Capital is designed to distinguish the firm from Fidelity’s considerable mutual fund business.

F-Prime will be stage agnostic in terms of its investment. Aalto adds that in addition to biotech, F-Prime will opportunistically consider investments in some FinTech companies. “There’s a lot of opportunity in that sector right now and we have some people on the team with unique expertise in that area,” he explains.

To date, the firms that make up F-Prime have invested in more than 89 companies across five funds. Portfolio companies include patient-scheduling software company Kyruus and tuition payments company Flywire.

 
This article was published in Opalesque's Private Equity Strategies our monthly research update on the global private equity landscape including all sectors and market caps.
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies


Today's Exclusives
Today's Other Voices
More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1